Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.
Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators.
Additional safety data on testosterone therapy are needed before it can be used to prevent type 2 diabetes.
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.
According to the American College of Physicians’ guideline, clinicians should prescribe testosterone treatment only to men with sexual dysfunction symptoms.
Benefits include significant improvement in body composition measurements over 6 months.
Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.
Study reveals an approximately 2-fold increased odds of venous thromboembolism associated with testosterone therapy in men with or without hypogonadism
Rates of screening, treatment for low testosterone higher for prolonged versus short-term opioid users